BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 8137344)

  • 1. Pharmacokinetics and metabolism of vinca alkaloids.
    Rahmani R; Zhou XJ
    Cancer Surv; 1993; 17():269-81. PubMed ID: 8137344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical and clinical pharmacology of vinca alkaloids.
    Zhou XJ; Rahmani R
    Drugs; 1992; 44 Suppl 4():1-16; discussion 66-9. PubMed ID: 1283846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uptake and metabolism of vinca alkaloids by freshly isolated human hepatocytes in suspension.
    Zhou XJ; Placidi M; Rahmani R
    Anticancer Res; 1994; 14(3A):1017-22. PubMed ID: 8074443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical pharmacokinetics of vinorelbine (Navelbine).
    Wargin WA; Lucas VS
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):21-7. PubMed ID: 7973765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human pharmacokinetics of a new Vinca alkaloid S 12363 with use of a monoclonal antibody-based radio- or enzyme immunoassay.
    Lelievre E; Guillaudeux J; Cardona H; Bourguignat A; Lokiec F; Solere P; Lucas C; Sauveur C
    Cancer Res; 1993 Aug; 53(15):3536-40. PubMed ID: 8339259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vinca alkaloid and MDR1].
    Takigawa N; Tanimoto M
    Gan To Kagaku Ryoho; 2008 Jul; 35(7):1086-9. PubMed ID: 18633246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analytical limits in clinical pharmacokinetics: example of vinca-alkaloids].
    Solere P; Lucas C
    Bull Cancer; 1991; 78(9):775-87. PubMed ID: 1751829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of the antitumor drug navelbine (5'-noranhydrovinblastine).
    Rahmani R; Bruno R; Iliadis A; Favre R; Just S; Barbet J; Cano JP
    Cancer Res; 1987 Nov; 47(21):5796-9. PubMed ID: 3664483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats.
    Rahmani R; Guéritte F; Martin M; Just S; Cano JP; Barbet J
    Cancer Chemother Pharmacol; 1986; 16(3):223-8. PubMed ID: 3698163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse.
    Dorr RT; Alberts DS
    J Natl Cancer Inst; 1985 Jan; 74(1):113-20. PubMed ID: 3855472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma pharmacokinetics of vinblastine and the investigational Vinca alkaloid N-(deacetyl-O-4-vinblastoyl-23)-L-ethyl isoleucinate in mice as determined by high-performance liquid chromatography.
    van Tellingen O; Beijnen JH; Nooijen WJ; Bult A
    Cancer Res; 1993 May; 53(9):2061-5. PubMed ID: 8481908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.
    Zhou-Pan XR; Sérée E; Zhou XJ; Placidi M; Maurel P; Barra Y; Rahmani R
    Cancer Res; 1993 Nov; 53(21):5121-6. PubMed ID: 8221648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of apovincaminic acid in dogs.
    Vereczkey L; Pudleiner P
    Pol J Pharmacol Pharm; 1987; 39(2):161-5. PubMed ID: 3432163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QM and QM/MD simulations of the Vinca alkaloids docked to tubulin.
    Kelly EB; Tuszynski JA; Klobukowski M
    J Mol Graph Model; 2011 Sep; 30():54-66. PubMed ID: 21798777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical pharmacokinetics of vinca alkaloids].
    Rahmani R; Samak R; Bore P; Cano JP
    Bull Cancer; 1988; 75(2):195-200. PubMed ID: 3359064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Snail neurons as a possible model for testing neurotoxic side effects of antitumor agents: paracrystal formation by Vinca alkaloids.
    Müller LJ; Moorer-van Delft CM; Roubos EW
    Cancer Res; 1988 Dec; 48(24 Pt 1):7184-8. PubMed ID: 3191492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive interaction of bisbenzylisoquinoline alkaloid, cepharanthin, with vinca alkaloid agents against human tumors.
    Ono M; Tanaka N
    In Vivo; 1997; 11(3):233-41. PubMed ID: 9239517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid.
    Schutz FA; Bellmunt J; Rosenberg JE; Choueiri TK
    Expert Opin Drug Saf; 2011 Jul; 10(4):645-53. PubMed ID: 21524237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug delivery systems and combination therapy by using vinca alkaloids.
    Lee CT; Huang YW; Yang CH; Huang KS
    Curr Top Med Chem; 2015; 15(15):1491-500. PubMed ID: 25877096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports.
    Chan JD
    Pharmacotherapy; 1998; 18(6):1304-7. PubMed ID: 9855331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.